Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

by Manali Phadke, Lily L. Remsing Rix, Inna Smalley, Annamarie T. Bryant, Yunting Luo, Harshani R. Lawrence, Braydon J. Schaible, Yian A. Chen, Uwe Rix, Keiran S. M. Smalley
Published 2018-01-01

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.

by Brijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, Mercedes Lioni, Min Xiao, Jun Kong, Clemens Krepler, Adina Vultur, Keith T Flaherty, Katherine L Nathanson, Keiran S M Smalley, Meenhard Herlyn
Published 2013-01-01

Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment.

by Nicholas J Taylor, Irina Gaynanova, Steven A Eschrich, Eric A Welsh, Timothy J Garrett, Chris Beecher, Ritin Sharma, John M Koomen, Keiran S M Smalley, Jane L Messina, Peter A Kanetsky
Published 2020-01-01

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling

by Qing Yin, Tao Han, Bin Fang, Guolin Zhang, Chao Zhang, Evan R. Roberts, Victoria Izumi, Mengmeng Zheng, Shulong Jiang, Xiu Yin, Minjung Kim, Jianfeng Cai, Eric B. Haura, John M. Koomen, Keiran S. M. Smalley, Lixin Wan
Published 2019-04-01

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanomaResearch in context

by Inna Smalley, Eunjung Kim, Jiannong Li, Paige Spence, Clayton J. Wyatt, Zeynep Eroglu, Vernon K. Sondak, Jane L. Messina, Nalan Akgul Babacan, Silvya Stuchi Maria-Engler, Lesley De Armas, Sion L. Williams, Robert A. Gatenby, Y. Ann Chen, Alexander R.A. Anderson, Keiran S.M. Smalley
Published 2019-10-01